Objective: To investigate the potential comorbidity biomarkers for Type 2 Diabetes Mellitus (T2DM) and Alzheimer’s disease (AD). Methods: This is a randomized case-control study. There are three groups: 1) normal control group included 32 healthy elderly people in the hospital physical examination; 2) 30 patients with T2DM group; and 3) AD group has 28 cases. On-line reversed-phase liquid chromatography separation, tandem mass spectrometry analysis and iTRAQ quantification were used for identification of peptidomic analysis, then detection of three comorbidity biomarkers might be associated with T2DM and AD by ELISA. Results: The Peptidomic Analysis of the potential comorbidity biomarkers for T2DM and the AD group includes Osteopontin (OPN), Isoform 2 of Histone H2Btype 2-F and Histone H4. These potential comorbidity biomarkers for T2DM and the AD group are significantly increased than normal control group. OPN concentrations are 1.67 (0.13 - 2.63) mmol/L in the normal control group, 3.15 (1.51 - 5.35) mmol/L in the T2DM group, and 7.66 (3.55 - 15.38) mmol/L in the AD group. Histone H4 concentrations in three groups respectively are 0.21 ± 0.036 mmol/L (normal control), 0.21 ± 0.046 mmol/L (T2DM) and 0.21 ± 0.034 mmol/L(AD). Isoforms 2 of Histone H2Btype 2-F are 1.73 (0.12 - 2.60) mmol/L, 4.71 (1.26 - 6.84) mmol/L and 9.30 (0 - 20.8) mmol/Lin three groups respectively. Conclusion: The inflammatory mechanism may lead to an increase of histone content in the urine of AD and T2DM patients. Clinical test of these potential comorbidity biomarkers Histones and Osteopontin would be the diagnosis of comorbidity AD and T2DM.
Gtz, J., Ittner, L.M. and Lim, Y.A. (2009) Common Features between Diabetes Mellitus and Alzheimer’s Disease. Cellular and Molecular Life Sciences, 66, 1321-1325. https://doi.org/10.1007/s00018-009-9070-1
Jin, W. and Patti, M.E. (2009) Genetic Determinants and Molecular Pathways in the Pathogenesis of Type 2 Diabetes. Clinical Science, 116, 99-111. https://doi.org/10.1042/CS20080090
Paolisso, G. and Giugliano, D. (1996) Oxidative Stress and Insulin Action: Is There a Relationship? Diabetologia, 39, 357-363. https://doi.org/10.1007/s001250050454
Beydoun, M.A., Lhotsky, A., Wang, Y., Dal Forno, G., An, Y., Metter, E.J., Ferrucci, L., O’Brien, R. and Zonderman, A.B. (2008) Association of Adiposity Status and Changes in Early to Mid-Adulthood with Incidence of Alzheimer’s Disease. American Journal of Epidemiology, 168, 1179-1189. https://doi.org/10.1093/aje/kwn229
Dela Monte, S.M. and Wands, J.R. (2008) Alzheimer’s Disease Is Type 3 Diabetes-Evidence Reviewed. Journal of Diabetes Science and Technology, 2, 1101-1113. https://doi.org/10.1177/193229680800200619
Qiu, W.Q. and Folstein, M.F. (2006) Insulin, Insulin-Degrading Enzyme and Amyloid-Beta Peptide in Alzheimer’s Disease: Review and Hypothesis. Neurobiology of Aging, 27, 190-198. https://doi.org/10.1016/j.neurobiolaging.2005.01.004
Mcgeer, P.L., Rogers, J. and Mcgeer, E.G. (1994) Neuroimmune Mechanisms in Alzheimer Disease Pathogenesis. Alzheimer Disease & Associated Disorders, 8, 149-158. https://doi.org/10.1097/00002093-199408030-00001
Reddy, P.H., Tripathi, R., Troung, Q., Tirumala, K., Reddy, T.P., Anekonda, V., Shirendeb, U.P., Calkins, M.J., Reddy, A.P., Mao, P. and Manczak, M. (2012) Abnormal Mitochondrial Dynamics and Synaptic Degeneration as Early Events in Alzheimer’s Disease: Implications to Mitochondria-Targeted Antioxidant Therapeutics. Biochimica et Biophysica Acta, 1822, 639-649. https://doi.org/10.1016/j.bbadis.2011.10.011
Verdelho, A., Madureira, S., Moleiro, C., et al. (2010) White Matter Changes and Diabetes Predict Cognitive Decline in the Elderly: The LADIS Study. Neurology, 75, 160-167. https://doi.org/10.1212/WNL.0b013e3181e7ca05
Kawarabayashi, T., Shoji, M., Younkin, L.H., et al. (2004) Dimeric Amyloid Beta Protein Rapidly Accumulates in Lipid Rafts Followed by Apolipoprotein E and Phosphorylated Tau Accumulation in the Tg2576 Mouse Model of Alzheimer’s Disease. Journal of Neuroscience, 24, 3801-3809. https://doi.org/10.1523/JNEUROSCI.5543-03.2004
Yan, L.M., Velkova, A., Tatarek-Nossol, M., et al. (2007) IAPP Mimic Blocks A Beta Cytotoxic Self-Assembly: Cross-Suppression of Amyloid Toxicity of A Beta and IAPP Suggests a Molecular Link between Alzheimer’s Disease and Type II Diabetes. Angewandte Chemie International Edition, 46, 1246-1252. https://doi.org/10.1002/anie.200604056
Kahn, S.E., Andrikopoulos, S. and Verchere, C.B. (1999) Islet Amyloid: A Long-Recognized But Underappreciated Pathological Feature of Type 2 Diabetes. Diabetes, 48, 241-253. https://doi.org/10.2337/diabetes.48.2.241
Abbas, T., Faivre, E. and Hlscher, C. (2009) Impairment of Synaptic Plasticity and Memory Formation in GLP-1 Receptor KO Mice: Interaction between Type 2 Diabetes and Alzheimer’s Disease. Behavioural Brain Research, 205, 265-271. https://doi.org/10.1016/j.bbr.2009.06.035
Wang, J., Yao, L., Li, B., Meng, Y., Ma, X., Lai, Y., Si, E., Ren, P., Yang, K., Shang, X. and Wang, H. (2016) Comparative Proteomic Analysis of Cultured Suspension Cells of the Halophyte Halogetonglomeratus by iTRAQ Provides Insights into Response Mechanisms to Salt Stress. Frontiers in Plant Science, 7, 110. https://doi.org/10.3389/fpls.2016.00110
Silva, P.F., Garcia, V.A., Domelles Ada, S., et al. (2012) Memory Impairment Induced by Brain Iron Overload Is Accompanied by Reduced H3K9 Acetylation and Ameliorated by Sodium Butyrate. Neuroscience, 200, 42-49. https://doi.org/10.1016/j.neuroscience.2011.10.038
Fischer, A., Sananbenesi, F., Mungenast, A., et al. (2010) Targeting the Correct HDAC(s) to Treat Cognitive Disorders. Trends in Pharmacological Sciences, 31, 605-617. https://doi.org/10.1016/j.tips.2010.09.003
Perez, M., Santa-Maria, I., Gomez de Barreda, E., et al. (2009) Tau-An Inhibitor of Deacetylase HDAC6 Function. Journal of Neurochemistry, 109, 1755-1766. https://doi.org/10.1111/j.1471-4159.2009.06102.x
Huang, H., Chen, H.W., Evankovich, J., et al. (2013) Histones Activate the NLRP3 Inflammasome in Kupffer Cells during Sterile Inflammatory Liver Injury. The Journal of Immunology, 191, 2665-2679. https://doi.org/10.4049/jimmunol.1202733
Friggeri, A., Banerjee, S., Xie, N., et al. (2012) Extracellular Histones Inhibit Efferocytosis. Molecular Medicine, 18, 825-833. https://doi.org/10.2119/molmed.2012.00005
Pemberton, A.D. and Brown, J.K. (2010) In Vitro Interactions of Extracellular Histones with LDL Suggest a Potential Proatherogenic Role. PLoS ONE, 5, e9884. https://doi.org/10.1371/journal.pone.0009884
Susztak, K., Bottinger, E., Novetsky, A., et al. (2004) Molecular Profiling of Diabetic Mouse Kidney Reveals Novel Genes Linked to Glomerular Disease. Diabetes, 53, 784-794. https://doi.org/10.2337/diabetes.53.3.784
Yamaguehi, H., Igarashi, M., Hirata, A., et al. (2004) Progression of Diabetic Nephropathy Enhances the Plasma Osteopontin Level in Type 2 Diabetic Patients. Endocrine Journal, 51, 499. https://doi.org/10.1507/endocrj.51.499
Lorenzen, J., Shah, R., Biser, A., et al. (2008) The Role of Osteopontin in the Development of Albuminuria. Journal of the American Society of Nephrology, 19, 884-890. https://doi.org/10.1681/ASN.2007040486
Nicholas, S.B., Liu, J., Kim, J., et al. (2010) Critical Role for Osteopontin in Diabetic Nephrnpathy. Kidney International, 77, 588-600. https://doi.org/10.1038/ki.2009.518
Wirths, O., Breyhan, H., Marcello, A., et al. (2010) Inflammatory Changes Are Tightly Associated with Neurodegeneration in the Brain and Spinal Cord of the APP/PS1KI Mouse Model of Alzheimer’s Disease. Neurobiology of Aging, 31, 747-757. https://doi.org/10.1016/j.neurobiolaging.2008.06.011
Simonsen, A.H., Mcguire, J., Hansson, O., et al. (2007) Novel Panel of Cerebrospinal Fluid Biomarkers for the Prediction of Progression to Alzheimer Dementia in Patients with Mild Cognitive Impairment. Archives of Neurology, 64, 366-370. https://doi.org/10.1001/archneur.64.3.366%